Start with its own history
At 36.80×, EW is 9.6% below its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
NYSE · EWMedical - DevicesUpdated Nov 4, 2026
Edwards Lifesciences Corporation P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
36.80×
9.6% belowthe 10-year annual average
Share price99.37
÷Earnings per share2.7
Price and EPS in quote currency. Calculation details
Investors are paying 36.80 for every 1 of reported earnings per share.
P/E over time
2016 – 2025
Annual P/ESelected-period average 40.73×
3-year average29.98×3 positive annual observations
5-year average34.81×5 positive annual observations
10-year average40.73×10 positive annual observations
Peer median · TTM32.50×6 peers with positive P/E
Historical P/E ratios
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2025 | 46.33× | +336.8% |
| Dec 31, 2024 | 10.61× | -67.9% |
| Dec 31, 2023 | 33.01× | +8.8% |
| Dec 31, 2022 | 30.33× | -43.6% |
| Dec 31, 2021 | 53.76× | -22.2% |
| Dec 31, 2020 | 69.11× | +49.3% |
| Dec 31, 2019 | 46.29× | +4.3% |
| Dec 31, 2018 | 44.40× | +15.8% |
View all 25 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2017 | 38.34× | +9.2% |
| Dec 31, 2016 | 35.09× | +2.6% |
| Dec 31, 2015 | 34.19× | +104.5% |
| Dec 31, 2014 | 16.72× | -10.0% |
| Dec 31, 2013 | 18.58× | -46.8% |
| Dec 31, 2012 | 34.95× | +3.8% |
| Dec 31, 2011 | 33.67× | -20.0% |
| Dec 31, 2010 | 42.10× | +97.8% |
| Dec 31, 2009 | 21.29× | -11.7% |
| Dec 31, 2008 | 24.10× | +0.6% |
| Dec 31, 2007 | 23.95× | +16.1% |
| Dec 31, 2006 | 20.63× | -34.6% |
| Dec 31, 2005 | 31.52× | -97.7% |
| Dec 31, 2004 | 1375.36× | +5935.4% |
| Dec 31, 2003 | 22.79× | -15.9% |
| Dec 31, 2002 | 27.11× | N/M |
| Dec 31, 2001 | N/M | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How EW compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 EW This stockEdwards Lifesciences Corporation | 36.80× |
 AVRAnteris Technologies Global Corp. | N/M |
 LIVNLivaNova PLC | 26.31× |
 AORTArtivion, Inc. | N/M |
 688617.SSAPT Medical Inc. | 38.15× |
 PENPenumbra, Inc. | 80.81× |
 ISRGIntuitive Surgical, Inc. | 57.60× |
 TRUMYTerumo Corporation | 21.26× |
 GNGBYGetinge AB (publ) | 26.85× |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does EW’s P/E tell you?
Compare like with like
The median of the 6 positive peer ratios above is 32.50×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take EW into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("EW", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 99.37 ÷ EPS 2.7 = 36.80×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 4, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
EW P/E ratio: common questions
The essentials behind the numbers.
Edwards Lifesciences Corporation's current P/E is 36.80× based on the quote data last updated Nov 4, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.